A parallel study showed administrations of ASOs targeting DGAT2 in HFD-fed mice and ob/ob mice both efficiently reduced liver Dgat2, resulting in lowered intrahepatic TG level and attenuated hyperlipidemia, as well as reduction of hepatic steatosis.309. The gene discussed is DGAT2; the disease is hyperlipidemia.